Novel Cancer Vaccine Prevents Melanoma From Returning in First for mRNA
The interim Phase III results showed the combination met its goals, and Moderna shares rose 40% in premarket trading, the companies said.
- On Wednesday, Merck and Moderna reported their personalized mRNA vaccine, Intismeran, combined with Keytruda reduced melanoma recurrence compared with Keytruda alone, marking the first positive late-stage trial results for an mRNA cancer vaccine.
- The ongoing Phase III trial randomized 1,137 patients with high-risk stage IIB through IV melanoma to receive Keytruda plus up to nine vaccine doses or Keytruda alone, building on earlier mid-stage findings.
- Moderna tailors each vaccine to the individual patient by analyzing mutations within their tumor, a highly targeted design requiring up to nine doses to administer the Intismeran treatment effectively.
- Following the announcement, Moderna shares jumped 40% and Merck rose 2%, with the companies reporting no new safety concerns and that the treatment met primary and secondary trial endpoints.
- January data showed the combination reduced melanoma recurrence or death risk by 49% after five years; the companies plan to present new data at an upcoming medical conference and share results with regulators.
44 Articles
44 Articles
Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial
A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have finally crossed the line from promising to proven.
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing skin cancer from returning or spreading in a study of melanoma patients.
An experimental melanoma vaccine, developed by Merck and Moderna, showed positive results in its first advanced clinical study. This was announced by the two companies in a note reported by CNBC. (ANSA)
Moderna shares climb nearly 100% as mRNA vaccine with Merck succeeds in large trial for skin cancer
The study is ongoing, but interim results found the treatment, Intismeran, met both its primary target of reducing cancer recurrence and its secondary goal of keeping cancers from spreading to other parts of the body
The results, foreplay, make us hope for a mRna solution. The pharmaceutical company earns 96% in premarket on Wall Street
Coverage Details
Bias Distribution
- 39% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
